Other income/(expense), net 1,905 0 1,905
Income before taxes 55,932 (4,009) 59,941
Tax expense 17,733 (1,341) 19,074
NET INCOME 38,199 (2,668) $40,867
Net income per common share
assuming dilution $1.43 ($0.10) $1.53
Weighted average number of shares
Basic 25,881 25,881 25,881
Diluted 26,776 26,776 26,776
Profit Margins:
Gross profit 49.8% 49.8%
R&D 4.9% 4.9%
S,G&A 31.6% 30.6%
Operating income 13.2% 14.3%
Income before taxes 14.8% 15.9%
Net income 10.1% 10.8%
12/30/06
Resolution Restruc- 12/30/06
12/30/06 of Tax turing As
As Contingen- Arryx Costs Adjusted
Reported cies (5) IPRD (6) (3) (7)
NET REVENUES $332,688 $0 $0 $0 $332,688
Gross profit 168,953 0 0 0 168,953
R&D 17,570 0 0 0 17,570
S,G&A 105,258 0 0 2,932 102,326
In-Process R&D 9,073 0 9,073 0 0
Operating expenses 131,901 0 9,073 2,932 119,896
Operating income 37,052
'/>"/>
SOURCE Haemonetics Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine news :1.
Landauer, Inc. Reports Strong Fiscal 2008 First Quarter Results2.
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 20073.
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company4.
Nutraceutical Reports Fiscal 2008 Q1 Results5.
Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share6.
Accuray Reports Continued Growth in Second Quarter of Fiscal 20087.
Cardinal Health Reports Second Quarter Results, Revises EPS Outlook8.
Encision Reports Third Fiscal Quarter Results9.
Zimmer Reports Fourth Quarter and 2007 Financial Results10.
Amylin Pharmaceuticals Reports 2007 Financial Results11.
Cystic Fibrosis Foundation reports upward trend for key health outcomes